RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults
V. Cárdenas (Spring House, PA, United States of America), M. Le Gars (Leiden, Netherlands), J. Sadoff (Leiden, Netherlands), J. Ruiz Guiñazú (Beerse, Belgium), N. Vaissière (Beerse, Belgium), C. Truyers (Beerse, Belgium), G. Scheper (Leiden, Netherlands), F. Struyf (Beerse, Belgium), J. Hendriks (Leiden, Netherlands), H. Schuitemaker (Leiden, Netherlands), M. Douoguih (Leiden, Netherlands)
Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Cárdenas (Spring House, PA, United States of America), M. Le Gars (Leiden, Netherlands), J. Sadoff (Leiden, Netherlands), J. Ruiz Guiñazú (Beerse, Belgium), N. Vaissière (Beerse, Belgium), C. Truyers (Beerse, Belgium), G. Scheper (Leiden, Netherlands), F. Struyf (Beerse, Belgium), J. Hendriks (Leiden, Netherlands), H. Schuitemaker (Leiden, Netherlands), M. Douoguih (Leiden, Netherlands). RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults. 489
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 146s Year: 2002
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol Source: Eur Respir J 2016; 48: 320-330 Year: 2016
The safety and immunogenicity of a conjugated nicotine vaccine: results from a double-blind, placebo-controlled trial in healthy smokers and non-smokers Source: Annual Congress 2004 - Update on smoking related damage and cessation Year: 2004
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003
A multicenter randomized phase III-trial with carboplatin (C) and paclitaxel (P) in advanced NSCLC: preliminary results of dose adjusted weekly schedule, compared to standard regime (q3w) Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Effects of exercise training after lung transplantation: 1 year follow-up of a randomized controlled trial Source: Annual Congress 2011 - Exercise training: new populations, new techniques Year: 2011
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
A randomized, open-label, parallel design study to compare the immunogenicity of simultaneous administration versus sequential administration of quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomised placebo-controlled trial Source: Eur Respir J 2005; 26: Suppl. 49, 278s Year: 2005
Safety and immunogenicity of a dose-sparing, trivalent inactivated seasonal influenza vaccine containing an advax adjuvant – a phase 1/2 randomised controlled trial Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020 Year: 2020
Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021